Newsroom

Blog

Enabling Precision Medicine for Breast Cancer Patients

Approximately every 2 minutes, a woman in the U.S. is diagnosed with breast cancer1. This high prevalence has led to rigorous standards of practice, from diagnosis to treatment.

Read More

Precision Medicine

Precision medicine reduces unnecessary risks to patients including hazardous side effects as well as ineffective treatments (“trial and error” medicine).

Read More
Written By:
JamesYen.jpg
James Yen

Talking Cancer: Conversations with Trailblazers, Advocates, Patients and Medical Ambassadors

As a premier reference lab and global pharma services organization that runs over a million oncology tests annually, NeoGenomics Laboratories, Inc.

Read More
Written By:
MadhuGhosh.jpg
Madhu Ghosh

Jemperli blog post - please share your thoughts!

We were glad to see FDA’s combined approval for GSK’s Jemperli (dostarlimab) and Ventana’s MMR RxDx for recurrent or advanced endometrial cancer back in April.

Read More
Written By:
scottreid.jpg
Scott Reid

Biomarker Types and CDx Biomarkers

The field of precision medicine is rooted in biomarker guided therapy. These biomarkers come in various forms as well as are categorized depending on use cases.

Read More
Written By:
JamesYen.jpg
James Yen

Liquid Biopsies

Despite the terminology “liquid biopsies” (LBx) becoming common place in diagnostic lexicon, as a routine clinical technology, LBx is still very much in its infancy.

Read More
Written By:
JamesYen.jpg
James Yen

TriCon 2021 Perspective

It was no surprise that Molecular Med Tri-Con 2021 was a virtual event this year.

Read More
Written By:
JamesYen.jpg
James Yen

Why does IHC remain so popular for CDx development?

The topic of IHC came up recently. Specifically, why is it used so frequently for companion diagnostic development.

Read More
Written By:
scottreid.jpg
Scott Reid

Contact Us To Get Started!

Work with us – your premier oncology partner – to optimize cancer care for patients